Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Modulation of 4′-(9-Acridinylamino)methanesulfon-m-anisidide-induced, Topoisomerase II-mediated DNA Cleavage by Gossypol

Ramesh C. Adlakha, Cheryl L. Ashorn, Diana Chan and Leonard A. Zwelling
Ramesh C. Adlakha
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl L. Ashorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Chan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonard A. Zwelling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 1989
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Our earlier studies have shown that gossypol [1,1′,6,6′,7,7′-hexahydroxy-5,5-diisopropyl - 3,3′-dimethyl - (2,2′-binaphthalene)-8,8′- dicarboxyaldehyde], a male contraceptive, inhibits DNA synthesis by decreasing the activities of DNA polymerase α and β, resulting in the arrest of cells in mid-S phase [L.J. Rosenberg, R.C. Adlakha, D.M. Desai, and P.N. Rao, Biochim. Biophys. Acta, 866: 258–267, 1986]. Now we have examined the effects of gossypol on another enzyme of importance to cellular functions, topoisomerase II (topo II). We have determined the consequences of gossypol treatment on 4′-(9-acridinylamino)methanesulfon-m anisidide (m-AMSA)-induced topoisomerase II-mediated, protein-associated DNA cleavage using the alkaline elution technique. In HeLa cells pretreated with gossypol (3.4–17.5 µm) for 8–16 h we observed a dose- and time-dependent decrease (50–75%) in DNA cleavage compared to that quantified in cells treated with m-AMSA alone. Gossypol by itself did not induce more than 25 rad-equivalents of DNA single-strand breaks even at the highest dose tested (26 µm). [14C]m-AMSA uptake was identical in treated and untreated cells. Pretreatment of cells with another inhibitor of DNA synthesis, thymidine, which blocks cells at G1/S boundary increased the m-AMSA-induced DNA cleavage by 25%, suggesting that the effect of gossypol might be due to the arrest of cells in mid-S phase. In contrast to gossypol's effects on m-AMSA-induced DNA cleavage, m-AMSA-induced cytotoxicity was actually increased in gossypol pretreated cells. Gossypol blocked topo II strand passing activity (decatenation of kinetoplast DNA) of cellular extracts from HeLa cells. The inhibition of this activity by gossypol was synergistic with the inhibition produced by m-AMSA or etoposide. These data suggest that gossypol can both inhibit topo II catalytic activity and interfere with the stabilization of topo II-DNA complex formation by m-AMSA. These data indicate that the magnitude of m-AMSA-induced DNA cleavage may not necessarily parallel the magnitude of m-AMSA-induced cytotoxicity. The cytotoxicity data may rather be explained by an action of gossypol and m-AMSA to block topo II catalytic activity at a point in the enzyme's strand passing cycle prior to cleavage complex formation that might be particularly toxic to cells in S phase. Gossypol should therefore be useful in improving our understanding of the cellular role of topo II and the consequences of interference with topo II activity by active antineoplastic agents.

Footnotes

  • ↵1 This work was supported by a grant from the Rockefeller Foundation to R. C. A. and by Grants CA-40090 and RR5511-23, awarded by the National Cancer Institute, Department of Health and Human Services, CH-324B from the American Cancer Society, and a gift of the M. D. Anderson Annual Fund for the Chemotherapy Research Program from Henry C. Beck, Jr. of Dallas, TX, to L. A. Z.

  • ↵2 To whom requests for reprints should be addressed, at Department of Medical Oncology, (Box 19) The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.

  • Received July 29, 1988.
  • Revision received January 9, 1989.
  • Accepted January 17, 1989.
  • ©1989 American Association for Cancer Research.
PreviousNext
Back to top
April 1989
Volume 49, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Modulation of 4′-(9-Acridinylamino)methanesulfon-m-anisidide-induced, Topoisomerase II-mediated DNA Cleavage by Gossypol
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Modulation of 4′-(9-Acridinylamino)methanesulfon-m-anisidide-induced, Topoisomerase II-mediated DNA Cleavage by Gossypol
Ramesh C. Adlakha, Cheryl L. Ashorn, Diana Chan and Leonard A. Zwelling
Cancer Res April 15 1989 (49) (8) 2052-2058;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Modulation of 4′-(9-Acridinylamino)methanesulfon-m-anisidide-induced, Topoisomerase II-mediated DNA Cleavage by Gossypol
Ramesh C. Adlakha, Cheryl L. Ashorn, Diana Chan and Leonard A. Zwelling
Cancer Res April 15 1989 (49) (8) 2052-2058;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Increased Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Cancer Patients
Show more Basic Sciences

Preclinical Pharmacology and Experimental Therapeutics

  • Potentiation of Mitomycin C and Porfiromycin Antitumor Activity in Solid Tumor Models by Recombinant Human Interleukin 1α
  • Pharmacokinetics of Pyrazoloacridine in the Rhesus Monkey
  • Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugates
Show more Preclinical Pharmacology and Experimental Therapeutics

Articles

  • Potentiation of Mitomycin C and Porfiromycin Antitumor Activity in Solid Tumor Models by Recombinant Human Interleukin 1α
  • Pharmacokinetics of Pyrazoloacridine in the Rhesus Monkey
  • Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugates
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement